Printer Friendly

Adipsin, MIP-1b, and IL-8 as CSF Biomarker Panels for ALS Diagnosis.

1. Introduction

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive and selective death of upper and lower motor neurons, in the cerebral cortex and spinal cord. To date, there is no effective treatment for this disease or known etiology. Since the identification of SOD1 as a causative gene of ALS, over the past two decades, at least 30 genes have been identified to be associated with ALS. Unlike familial ALS, the causes of sporadic ALS, which accounts for the majority of ALS cases (90-95%), remain unclear [1].

Recently, it has been suggested that ALS could be an autoimmune disease. The increase in activated microglia/macrophages, reactive astrocytes, and dendritic cells found in the postmortem brain and spinal cord of ALS patients supports the concept that an immune-mediated inflammatory process may contribute to ALS pathogenesis that includes proinflammatory cytokine increase in serum and cerebrospinal fluid (CSF) [2-5]. It has also been described that serum from ALS patients induces motor neuron death in vitro and in vivo in healthy mice yielding deterioration of motor neurons in the spinal cord and alters ion channel expression of the Na(v)1.6 and K(v)1.6 channels in newborn rat spinal motor neurons [6-9]. These recent observations suggest that a toxic event and primary or consequent immune response may eventually induce an apoptotic death of motor neurons. At the present time, these reports do not clarify whether inflammatory processes precede disease onset or result from it [10]. However, they suggest that an inflammatory activity may be present early in ALS and, according to Majoor-Krakauer et al. [11], it could trigger a catastrophic cascade of events leading toward selective motor neuron death in genetically susceptible subjects.

Multiplex cytokine analysis on the CSF of 41 ALS patients showed an increment of IL-10, IL-6, GM-CSF, IL-2, and IL-15 versus the concentrations of these cytokines in the CFS of subjects with other neurological diseases. Also, the expression of IL-8 was higher in those patients with lower levels of physical function [10]. The increase of proinflammatory cytokines has been correlated with increases in activation of microglia/macrophages, reactive astrocytes, and dendritic cells [2] that supports an inflammatory process occurring either at the initiation or at the progression of the disease.

Recently, a cytokine pathway analysis in the CSF of ALS patients report a negative correlation between IL-4 and IL-6 and shorter disease evolution towards death (<12 moths) and a positive correlation on patients with longer more settle disease progression (> 12 months) [6,12]. Adipsin, monocyte chemoattractant protein-1 (MCP-1), and macrophage inflammatory protein-1[beta] (MIP-1[beta]) increased concentrations have also been reported in the CSF of ALS patients. Although these cytokine CSF levels were higher in patients when compared to controls, no correlation with ALS clinical severity was observed [12, 13]. Nevertheless, disease duration was correlated positively with levels of MCP-1 [4]. The complement system in ALS suggests that activation may precede end-plate denervation in human ALS [14, 15].

ALS diagnosis is a challenging process due to its heterogenic clinical phenotype that overlaps with other neurodegenerative diseases. The diagnosis is based on the El Escorial and Airlie House clinical and neurophysiological criteria [16]. At the present time, there are no reliable biomarker panels that could aid the clinician to establish an early diagnosis, as well as to define prognosis [17]. C-reactive protein, selected interleukins, growth factors, neurofilaments, microRNA, and others, either in serum or in CSF, have been proposed as possible prognosis biomarkers [18-21]. Nevertheless, there is no consensus on which biomarkers are reliable as diagnostic factors in ALS. In this report, we describe a biomarker panel of CSF cytokine concentrations, obtained after applying a tree analysis and a PanelomiX program [22].

2. Material and Methods

2.1. Patient Samples. Seventy-seven patients between 26 and 77 years of age were recruited (mean age 48.5 [+ or -] 11.7) and evaluated for eligibility at the Neurology Service of the Hospital San Jose Tec de Monterrey, Mexico, from June 2005 to December 2010. As for the control group, 13 patients (mean age 39.15 [+ or -] 11.32 years) (61% female and 39% male), who underwent a complete neurological evaluation that included a spinal tap for disabling headaches were eventually diagnosed as having a tensional headache. All had normal CSF and head magnetic resonance imaging (MRI). The Ethics and Research Committees of Hospital San Jose and Medicine School from the Tecnologico de Monterrey approved the protocol, and all the participating patients and controls signed an informed consent. CSF was obtained by lumbar puncture, and aliquot of 2 ml from each patient was stored at -80[degrees]C.

2.2. Cytokine Analysis. Cytokine determination was performed by multiplex analysis of undiluted CSF supernatants using the Bio-Plex Human 17-plex panel of cytokines and growth factors (Bio-Rad; Hercules, CA) (Table 1). To avoid intra- and intertest determination variability, all CSF samples were analyzed at the same time. ALS patients were evaluated by means of the ALS functional rating scale revised (ALSFRS-R) at the time of the lumbar puncture.

2.3. Statistical Analysis. CSF concentrations of 19 cytokines of 77 ALS patients and 13 controls were analyzed by a nonparametric Mann-Whitney's U two-tailed test to identify differences in central tendencies between groups followed by a Kolmogorov-Smirnov test. Afterward, a linear discriminant analysis and a decision tree were fitted to the complete cases and different measures of classification error were performed. All analysis and graphs were developed using the R programming language (http://www.r-project.org/). For the biomarker panel analysis threshold, PanelomiX, a threshold-based algorithm, was applied (http://www.panelomix.net) [22].

3. Results

Applied classification tree analysis shows adipsin as the first filter. Levels of this protein greater than 7118 ng must likely define the sample as one coming from an ALS patient. On this sheet, 61 patients from 77 (79%) were detected. None of the controls presented such high levels. The second filter was IL-8, which was defined as this cytokine presenting levels under 19.82 ng. On the third filter, MIP-1b was established to be higher than 5.95 ng to confirm it as probably belonging to an ALS patient (Figure 1).

The applied decision tree to cytokine concentration on the CSF of the control group shows positive levels of adipsin; it must be lower than 7118.49 pg/ml with levels of IL-8 pg/ml higher than 19.82 pg/ml and concentrations of MIP-1b under 5.95 pg/ml. Figure 2.

This technique yielded an accuracy in the prediction of 98.7%, with a sensitivity of 100% and specificity of 91.6% when using all of the data; the resulting differences are shown in Figure 2. However, when performing fourfold cross-validation, the prediction error rate was greater, resulting in an accuracy of 75.32%, the sensibility of 81.53%, and specificity of 41.6%. When employing leave-one-out cross-validation, the accuracy and sensitivity were improved to 89.6% and 95.38%, respectively, although the specificity remained low at 58.33%.

Results generated with PanelomiX algorithm analysis show very similar results: the same proteins and their thresholds were positive as markers for ALS (Table 2). In addition to the three previous markers, adipsin, MIP-1b, and IL-8, IL-6 was also detected as a positive marker. ALS outcomes were positive when two of the cytokines coincide with the threshold in Table 2.

ROC curves obtained with four standard methods: PanelomiX algorithm, logistic regression, support vector machine (SVM), and decision tree, are shown in Figure 3. In there, we observed that the best results were obtained from PanelomiX and decision tree (Table 3).

4. Discussion

The search for possible markers for the diagnosis of ALS included cytokines, growth factors, specific neuronal proteins, and specific mutations [18-21]. However, to date, there is no reliable marker. In this work, we propose the combination of more than one marker that allows us to diagnose ALS with an acceptable sensitivity and specificity. The analysis of the concentrations of a panel of cytokines and their correlation between them allowed to determine that using the decision tree in patients with ALS had low values of IL-8 and high values of MIP-1b and adipsin. PanelomiX algorithm also show a threshold for adipsin, MIP-b1, IL-8, and IL-6 as markers for ALS. This program has shown to be useful to create panels of biomarkers by applying the interactive combination of biomarker and threshold (ICBT) method. The proposed combination model has been demonstrated to be advantageous for predicting the outcome in patients with aneurysmal subarachnoid haemorrhage [22] and prognosis in severe traumatic brain injury [23]. Also, it has been applied to discriminate between patients with lung cancer versus smokers [24, 25]. In a previous work, we reported the high values of MIP-1b and adipsin in patients with ALS [12, 13]. Added into this analysis and as a corollary, low values of IL-6 and IL-8 and high values of adipsin and MIP-1b could be taken into account as strong ALS markers. Between those cytokines, IL-8 represents an important factor to follow. Low values of IL-8 were also reported in multiple sclerosis patients [26]; nevertheless, other reports inform high levels of IL-8 in noninflammatory neurological diseases [27-31]. Because IL-8 induces angiogenesis and proliferation, it is possible that by decreasing its expression, it would reflect a poor recovery tissue capacity and faster disease progression [32, 33]. Also, high levels of IL-8 have been related with lower ALSFRS-R scores and as indicator of disease progression [10].

5. Conclusion

The analysis of the levels of IL-6, IL-8, MIP-b1, and adipsin could be part of a biomarker panel for the diagnosis of ALS alongside the clinical and neurophysiological criteria. These observations could also be important to a better understanding about the clinical outcome as well as the participation of inflammatory processes in the disease onset.

Data Availability

The cytokine concentration data used to support the findings of this study are included within the supplementary information file (available here).

https://doi.org/10.1155/2018/3023826

Conflicts of Interest

The authors declare that there are no competing interests regarding the publication of this article.

Acknowledgments

This work was partially funded by endowments from Tecnologico de Monterrey and the Zambrano-Hellion Foundation.

Supplementary Materials

Cytokine concentration determined on undiluted CSF supernatants by multiplex analysis of using the Bio-Plex Human 17-plex panel of cytokines and growth factors. (Supplementary Materials)

References

[1] S. Zarei, K. Carr, L. Reiley et al., "A comprehensive review of amyotrophic lateral sclerosis," Surgical Neurology International, vol. 6, no. 1, p. 171, 2015.

[2] J. S. Henkel, J. I. Engelhardt, L. Siklos et al., "Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue," Annals of Neurology, vol. 55, no. 2, pp. 221-235, 2004.

[3] M. Tanaka, H. Kikuchi, T. Ishizu et al., "Intrathecal upregulation of granulocyte colony stimulating factor and its neuroprotective actions on motor neurons in amyotrophic lateral sclerosis," Journal of Neuropathology & Experimental Neurology, vol. 65, no. 8, pp. 816-825, 2006.

[4] R. M. Mitchell, Z. Simmons, J. L. Beard, H. E. Stephens, and J. R. Connor, "Plasma biomarkers associated with ALS and their relationship to iron homeostasis," Muscle & Nerve, vol. 42, no. 1, pp. 95-103, 2010.

[5] H. R. Martinez, C. E. Escamilla-Ocanas, J. M. Tenorio-Pedraza et al., "Altered CSF cytokine network in amyotrophic lateral sclerosis patients: a pathway-based statistical analysis," Cytokine, vol. 90, pp. 1-5, 2017.

[6] M. Demestre, A. Pullen, R. W. Orrell, and M. Orth, "ALS-IgG-induced selective motor neurone apoptosis in rat mixed primary spinal cord cultures," Journal of Neurochemistry, vol. 94, no. 1, pp. 268-275, 2005.

[7] G. Almer, P. Teismann, Z. Stevic et al., "Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patients," Neurology, vol. 58, no. 8, pp. 1277-1279, 2002.

[8] A. H. Pullen, M. Demestre, R. S. Howard, and R. W. Orrell, "Passive transfer of purified IgG from patients with amyotrophic lateral sclerosis to mice results in degeneration of motor neurons accompanied by [Ca.sup.2+] enhancement," Acta Neuropathologica, vol. 107, no. 1, pp. 35-46, 2004.

[9] R. Gunasekaran, R. S. Narayani, K. Vijayalakshmi et al., "Exposure to cerebrospinal fluid of sporadic amyotrophic lateral sclerosis patients alters Nav1.6 and Kv1.6 channel expression in rat spinal motor neurons," Brain Research, vol. 1255, pp. 170-179, 2009.

[10] R. M. Mitchell, W. M. Freeman, W. T. Randazzo et al., "A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis," Neurology, vol. 72, no. 1, pp. 14-19, 2009.

[11] D. Majoor-Krakauer, P. J. Willems, and A. Hofman, "Genetic epidemiology of amyotrophic lateral sclerosis," Clinical Genetics, vol. 63, no. 2, pp. 83-101, 2003.

[12] H. R. Martinez, C. E. Escamilla-Ocanas, C. R. Camara-Lemarroy, M. T. Gonzalez-Garza, J. Moreno-Cuevas, and M. A. Garcia Sarreon, "Incremento de las citoquinas proteina quimiotactica de monocitos-1 (MCP-1) y proteina inflamatoria macrofagica-1[beta] (MIP-1[beta]) en liquido cefalorraquideo de pacientes con esclerosis lateral amiotrofica," Neurologia, 2017.

[13] H. R. Martinez, C. E. Escamilla-Ocanas, C. R. Camara-Lemarroy, M. T. Gonzalez-Garza, J. M. Tenorio-Pedraza, and M. Hernandez-Torre, "CSF concentrations of adipsin and adiponectin in patients with amyotrophic lateral sclerosis," Acta Neurologica Belgica, vol. 117, no. 4, pp. 879-883, 2017.

[14] T. M. Woodruff, K. J. Costantini, S. M. Taylor, and P. G. Noakes, "Role of complement in motor neuron disease: animal models and therapeutic potential of complement inhibitors," Advances in Experimental Medicine and Biology, vol. 632, pp. 143-158, 2008.

[15] N. Bahia el Idrissi, S. Bosch, V. Ramaglia, E. Aronica, F. Baas, and D. Troost, "Complement activation at the motor endplates in amyotrophic lateral sclerosis," Journal of Neuroinflammation, vol. 13, no. 1, p. 72, 2016.

[16] B. R. Brooks, R. G. Miller, M. Swash, and T. L. Munsat, "El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis," Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, vol. 1, no. 5, pp. 293-299, 2000.

[17] O. Hardiman, A. al-Chalabi, A. Chio et al., "Amyotrophic lateral sclerosis," Nature Reviews Disease Primers, vol. 3, article 17085, 2017.

[18] C. Lunetta, A. Lizio, E. Maestri et al., "Serum C-reactive protein as a prognostic biomarker in amyotrophic lateral sclerosis," JAMA Neurology, vol. 74, no. 6, pp. 660-667, 2017.

[19] X. W. Su, Z. Simmons, R. M. Mitchell, L. Kong, H. E. Stephens, and J. R. Connor, "Biomarker-based predictive models for prognosis in amyotrophic lateral sclerosis," JAMA Neurology, vol. 70, no. 12, pp. 1505-1511, 2013.

[20] L. T. Vu and R. Bowser, "Fluid-based biomarkers for amyotrophic lateral sclerosis," Neurotherapeutics, vol. 14, no. 1, pp. 119-134, 2017.

[21] M. A. van Es, O. Hardiman, A. Chio et al., "Amyotrophic lateral sclerosis," The Lancet, vol. 390, no. 10107, pp. 2084-2098, 2017.

[22] X. Robin, N. Turck, A. Hainard et al., "PanelomiX: a threshold-based algorithm to create panels of biomarkers," Translational Proteomics, vol. 1, no. 1, pp. 57-64, 2013.

[23] B. Walder, X. Robin, M. M. L. Rebetez et al., "The prognostic significance of the serum biomarker heart-fatty acidic binding protein in comparison with s100b in severe traumatic brain injury," Journal of Neurotrauma, vol. 30, no. 19, pp. 1631-1637, 2013.

[24] M. Calderon-Santiago, F. Priego-Capote, N. Turck et al., "Human sweat metabolomics for lung cancer screening," Analytical and Bioanalytical Chemistry, vol. 407, no. 18, pp. 5381-5392, 2015.

[25] A. Peralbo-Molina, M. Calderon-Santiago, F. Priego-Capote, B. Jurado-Gamez, and M. D. Luque de Castro, "Identification of metabolomics panels for potential lung cancer screening by analysis of exhaled breath condensate," Journal of Breath Research, vol. 10, no. 2, 2016.

[26] R. Yamasaki, H. Yamaguchi, T. Matsushita, T. Fujii, A. Hiwatashi, and J. I. Kira, "Early strong intrathecal inflammation in cerebellar type multiple system atrophy by cerebrospinal fluid cytokine/chemokine profiles: a case control study," Journal of Neuroinflammation, vol. 14, no. 1, p. 89, 2017.

[27] T. Matsushita, T. Tateishi, N. Isobe et al., "Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis," PLoS One, vol. 8, no. 4, article e61835, 2013.

[28] H. Blasco, G. Garcon, F. Patin et al., "Panel of oxidative stress and inflammatory biomarkers in ALS: a pilot study," Canadian Journal of Neurological Sciences, vol. 44, no. 1, pp. 9095, 2017.

[29] J. Ehrhart, A. J. Smith, N. Kuzmin-Nichols et al., "Humoral factors in ALS patients during disease progression," Journal of Neuroinflammation, vol. 12, no. 1, p. 127, 2015.

[30] S. T. Ngo, F. J. Steyn, L. Huang et al., "Altered expression of metabolic proteins and adipokines in patients with amyotrophic lateral sclerosis," Journal of the Neurological Sciences, vol. 357, no. 1-2, pp. 22-27, 2015.

[31] Y. Hu, C. Cao, X. Y. Qin et al., "Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: a meta-analysis study," Scientific Reports, vol. 7, no. 1, p. 9094, 2017.

[32] A. Li, S. Dubey, M. L. Varney, B. J. Dave, and R. K. Singh, "IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis," The Journal of Immunology, vol. 170, no. 6, pp. 3369-3376, 2003.

[33] D. J. J. Waugh and C. Wilson, "The interleukin-8 pathway in cancer," Clinical Cancer Research, vol. 14, no. 21, pp. 6735-6741, 2008.

Maria Teresa Gonzalez-Garza (iD), (1) Hector Ramon Martinez, (2) Delia E. Cruz-Vega (iD), (1) Martin Hernandez-Torre, (1) and Jorge E. Moreno-Cuevas (iD) (1)

(1) Tecnologico de Monterrey, Ave. Morones Prieto 3000, Escuela de Medicina y Ciencias de la Salud, Monterrey, NL, 64710, Mexico

(2) Tecnologico de Monterrey, Batallon de San Patricio 112, Instituto de Neurologia y Neurocirugia, Centro Medico Zambrano Hellion, San Pedro Garza Garcia, NL, 66278, Mexico

Correspondence should be addressed to Maria Teresa Gonzalez-Garza; mtgonzalezgarza@itesm.mx

Received 13 June 2018; Revised 15 August 2018; Accepted 28 August 2018; Published 10 October 2018

Academic Editor: Roberta Rizzo

Caption: Figure 1: Decision trees displaying the partitioning of the original space into subregions pertaining to one particular group.

Caption: Figure 2: Comparing concentration of adipsin, IL-8, and MIP-1b after classification by decision tree analysis applied to CSF cytokine on the ALS group and the control group.

Caption: Figure 3: ROC curves showing the comparison with other standard combination methods. Black: PanelomiX; blue: logistic regression; green: SVM; red: recursive partitioning (decision trees).
Table 1: Cytokines and growth factor determined by multiplex system.

Interleukin 1 (IL-1)    Interleukin 7 (IL-7)

Interleukin 2 (IL-2)    Interleukin 8 (IL-8)

Interleukin 4 (IL-4)   Interleukin 10 (IL-10)

Interleukin 5 (IL-5)   Interleukin 12 (IL-12)

Interleukin 6 (IL-6)   Interleukin 13 (IL-13)

Interleukin 1 (IL-1)       Interleukin 17 (IL-17)

Interleukin 2 (IL-2)        Granulocyte colony-
                         stimulating factor (G-CSF)

Interleukin 4 (IL-4)         Macrophage colony-
                         stimulating factor (M-CSF)

Interleukin 5 (IL-5)   Interferon gamma (IFN[gamma])

Interleukin 6 (IL-6)      Monocyte chemotactic and
                          activating factor (MCAF)

Interleukin 1 (IL-1)   Macrophage inflammatory
                           protein (MIP-1b)

Interleukin 2 (IL-2)    Tumor necrosis factor
                             (TNF[alpha])

Interleukin 4 (IL-4)           Adipsin

Interleukin 5 (IL-5)   Monocyte chemoattractant
                          protein-1 (MCP-1)

Interleukin 6 (IL-6)

Table 2: Positive markers for ALS disease obtained with PanelomiX
analysis.

Adipsin   MIP-1b   IL-6    IL-8

>           >       >       <
7118.69    5.89    4.59   22.445

Table 3: ROC analysis of panel and classical methods
(cross-validation).

                          % pAUC (95% CL)      % SP (95% CL)

PanelomiX                  0.0 (0.0-4.6)    100.0 (100.0-100.0)
Logistic regression        2.3 (1.8-4.5)    100.0 (100.0-100.0)
Decision trees             0.2 (0.0.3.8)    100.0 (100.0-100.0)
Support vector machines    2.1 (1.6-4.6)    100.0 (100.0-100.0)

                           % SE (95% CL)

PanelomiX                  0.0 (0.0-0.0)
Logistic regression       45.6 (30.9-54.4)
Decision trees             0.0 (0.0-0.0)
Support vector machines   42.6 (30.9-54.4)
COPYRIGHT 2018 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Gonzalez-Garza, Maria Teresa; Martinez, Hector Ramon; Cruz-Vega, Delia E.; Hernandez-Torre, Martin;
Publication:Disease Markers
Date:Jan 1, 2018
Words:3227
Previous Article:Clinical Impact and Prognostic Role of KRAS/BRAF/PIK3CA Mutations in Stage I Colorectal Cancer.
Next Article:Association between MnSOD Val16Ala Polymorphism and Cancer Risk: Evidence from 33,098 Cases and 37,831 Controls.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters